Peptides May Soon Be Legal. These Companies Are Ready To Cash In

With an FDA panel expected to recommend legal production of as many as seven peptides this week, compounding pharmacies and telehealth companies are preparing for the coming bonanza.

Mastercard Patented A Tool That Could Have Cracked This Summer’s Cyclospora Outbreak. It Was Never Deployed

Finding the lettuce took days. Finding Taco Bell took two months. Mastercard patented a fix in 2014 and shelved it, chasing the wrong half of the problem.

Coffee And Heart Health: Reassurance, Not A Prescription To Drink More

A new American Heart Association statement redefines coffee’s impact on heart health, moving from historical caution to reassurance.

The Grand Declicking

Healthcare has normalized click creep. Every extra checkbox steals attention from patients. It’s time for a Grand Declicking.

The U.S. Alone Votes Against A Road Safety Declaration

Yesterday the UN’s General Assembly passed a near-unanimous declaration on cutting road-traffic deaths in half.

Cyclospora False Positive? Why We Should Still Trust Outbreak Science

Cyclospora lab test retraction by FDA does not negate outbreak science.

Is Warren Buffett’s Stock Gambling Warning Bad For Biotechnology?

Buffett’s casino comments raise an uncomfortable truth. Is biotechnology an investment, or is it more of a gambling casino? The honest answer is that it can be either.

Genetic Testing Looking At The Whole Genome

New structural variation sequencing reads long stretches of fetal DNA to pinpoint duplications, flips, and rearrangements, revealing which changes truly matter.

Carrie Ann Inaba Talks About Her Challenges With Sjögren’s Disease

Carrie Ann Inaba, longtime Dancing with the Stars judge and former co-host of The Talk, talked about the many challenges she has faced with Sjögren’s disease.

FDA’s Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype

A FDA advisory committee will review evidence surrounding peptides. Experts are concerned there is a paucity of evidence to back their approval for legal compounding.